Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study).
Yamaguchi O, Kakizaki H, Homma Y, Igawa Y, Takeda M, Nishizawa O, Gotoh M, Yoshida M, Yokoyama O, Seki N, Okitsu A, Hamada T, Kobayashi A, Kuroishi K. Yamaguchi O, et al. Among authors: kuroishi k. Int J Urol. 2019 Mar;26(3):342-352. doi: 10.1111/iju.13868. Epub 2018 Dec 13. Int J Urol. 2019. PMID: 30548692 Free PMC article. Clinical Trial.
Cardiovascular safety of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A post hoc analysis from the Japanese MILAI II study.
Katoh T, Igawa Y, Yamaguchi O, Kato D, Hamada T, Kuroishi K. Katoh T, et al. Among authors: kuroishi k. Low Urin Tract Symptoms. 2020 Jan;12(1):68-80. doi: 10.1111/luts.12286. Epub 2019 Sep 30. Low Urin Tract Symptoms. 2020. PMID: 31571403 Free PMC article. Clinical Trial.
Efficacy of mirabegron, a β3 -adrenoreceptor agonist, in Japanese women with overactive bladder and either urgency urinary incontinence or mixed urinary incontinence: Post-hoc analysis of pooled data from two randomized, placebo-controlled, double-blind studies.
Takahashi S, Mishima Y, Kuroishi K, Ukai M. Takahashi S, et al. Among authors: kuroishi k. Int J Urol. 2022 Jan;29(1):7-15. doi: 10.1111/iju.14700. Epub 2021 Oct 4. Int J Urol. 2022. PMID: 34605079 Free PMC article. Clinical Trial.
High-dose linaclotide is effective and safe in patients with chronic constipation: A phase III randomized, double-blind, placebo-controlled study with a long-term open-label extension study in Japan.
Fukudo S, Miwa H, Nakajima A, Kinoshita Y, Kosako M, Hayashi K, Akiho H, Kuroishi K, Johnston JM, Currie M, Ohkusa T. Fukudo S, et al. Among authors: kuroishi k. Neurogastroenterol Motil. 2019 Jan;31(1):e13487. doi: 10.1111/nmo.13487. Epub 2018 Oct 23. Neurogastroenterol Motil. 2019. PMID: 30353619 Free PMC article. Clinical Trial.
Dose-finding study of linaclotide in Japanese patients with chronic constipation: A phase II randomized, double-blind, and placebo-controlled study.
Fukudo S, Miwa H, Nakajima A, Kinoshita Y, Kosako M, Nakagawa A, Akiho H, Kuroishi K, Johnston JM, Currie M, Ohkusa T. Fukudo S, et al. Among authors: kuroishi k. Neurogastroenterol Motil. 2018 Dec;30(12):e13442. doi: 10.1111/nmo.13442. Epub 2018 Aug 7. Neurogastroenterol Motil. 2018. PMID: 30084233 Clinical Trial.
Multi-center, randomized, double-blind, placebo-controlled study of quetiapine extended-release formulation in Japanese patients with bipolar depression.
Murasaki M, Koyama T, Kanba S, Takeuchi M, Shimizu Y, Arita E, Kuroishi K, Takeuchi M, Kamei S. Murasaki M, et al. Among authors: kuroishi k. Psychopharmacology (Berl). 2018 Oct;235(10):2859-2869. doi: 10.1007/s00213-018-4977-6. Epub 2018 Aug 1. Psychopharmacology (Berl). 2018. PMID: 30069587 Free PMC article. Clinical Trial.
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP3652, a Reversible Fatty Acid Amide Hydrolase Inhibitor, in Healthy, Nonelderly, Japanese Men and Elderly, Japanese Men and Women: A Randomized, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Phase I Study.
Takizawa M, Hatta T, Iitsuka H, Katashima M, Sato Y, Kuroishi K, Nagashima H. Takizawa M, et al. Among authors: kuroishi k. Clin Ther. 2020 May;42(5):906-923. doi: 10.1016/j.clinthera.2020.03.021. Epub 2020 May 23. Clin Ther. 2020. PMID: 32456804 Clinical Trial.
30 results